Replication-induced DNA damage after PARP inhibition causes G(2) delay, and cell line-dependent apoptosis, necrosis and multinucleation

PARP inhibitors have been approved for treatment of tumors with mutations in or loss of BRCA1/2. The molecular mechanisms and particularly the cellular phenotypes resulting in synthetic lethality are not well understood and varying clinical responses have been observed. We have investigated the dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Dale Rein, Idun, Solberg Landsverk, Kirsti, Micci, Francesca, Patzke, Sebastian, Stokke, Trond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825575/
https://www.ncbi.nlm.nih.gov/pubmed/26312527
http://dx.doi.org/10.1080/15384101.2015.1085137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825575/
https://www.ncbi.nlm.nih.gov/pubmed/26312527
http://dx.doi.org/10.1080/15384101.2015.1085137

Ejemplares similares